primary open-angle glaucoma

Precision medicine coming to glaucoma via specific pathwaysCharacterizing the genetic elements linked to different types of glaucoma, such as in the Primary Open-Angle African American Glaucoma Genetics study, could help clinicians develop more precise and effective treatments.
Engaging OCTA in glaucoma imaging
Engaging OCTA in glaucoma imagingA prospective, observational study found that eyes with mild POAG could be differentiated from pre-perimetric glaucomatous eyes, which also could be differentiated from normal eyes using OCTA-derived retinal vessel density measurements.
POAG: Enigmatic group of heterogenous diseases?Various subtypes of primary open-angle glaucoma might exist. Continued research is needed to identify the characteristics of each subtype for better management.
Poor oral health may be associated with POAG
Poor oral health may be associated with POAGRecent tooth loss and periodontal disease have been linked to primary open-angle glaucoma in a large prospective study of male health professionals.
New technology predicts conversion to POAGClinicians can predict which patients with ocular hypertension are most likely to develop primary open-angle glaucoma (POAG) using short-wave automated perimetry, scanning laser polimetry, and confocal laser ophthalmoscopy, as well as the patient’s age, researchers said.
Microstent approval makes big news in glaucoma world
Microstent approval makes big news in glaucoma worldClinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
Novel gelatin stent works effectively as stand-alone procedureOne-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma.
Santen to acquire InnFocus, developer of glaucoma drainage implantSanten Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.
MICS & MIGS: combined surgery with microstent devicesThe combination of MICS and MIGS can offer an effective surgical treatment for POAG when the reduction of IOP following cataract surgery alone is not sufficient to reduce a patient’s need for glaucoma therapies.
The who, what, when, why and how of selective laser trabeculoplastySelective laser trabeculoplasty is safe and effective for reducing IOP in patients with glaucoma. However, not all patients respond to treatment and its effects are not permanent even in those who respond well.